Clinical Trial Update: Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety and tolerability of the PET tracer [11C]CPPC in patients with amyotrophic lateral sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• [11C]CPPC (11C-CPPC)

Snippet

Sponsor: Johns Hopkins University | Conditions: Amyotrophic Lateral Sclerosis | Phase 1 | Status: TERMINATED